Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Genetics
|
| gptkbp:amino_acid_change |
valine to glutamic acid at position 600
|
| gptkbp:associated_with |
gptkb:Oncology
clinical outcomes increased cell proliferation increased angiogenesis increased tumor aggressiveness specific clinical features adverse effects of treatment response to immunotherapy increased mutation burden specific clinical trials specific therapeutic strategies differentiation of tumor types increased risk of metastasis specific patient demographics specific survival outcomes specific therapeutic targets |
| gptkbp:can_detect |
PCR testing
|
| gptkbp:cause |
uncontrolled cell growth
|
| gptkbp:clinical_trial |
ongoing research
|
| gptkbp:diagnosis |
biopsy
|
| gptkbp:genetic_studies |
missense mutation
higher in younger patients |
| https://www.w3.org/2000/01/rdf-schema#label |
BRAF V600 E mutation
|
| gptkbp:impact |
MAPK signaling pathway
survival rates |
| gptkbp:influences |
treatment decisions
treatment outcomes |
| gptkbp:initiated_by |
gptkb:vemurafenib
gptkb:dabrafenib |
| gptkbp:is_common_in |
Caucasian populations
|
| gptkbp:is_found_in |
tumor microenvironment
liquid biopsies tumor samples other cancers |
| gptkbp:is_linked_to |
disease progression
immune evasion mechanisms tumor heterogeneity specific biomarkers therapeutic resistance specific treatment regimens treatment efficacy studies resistance to certain therapies specific histological features treatment resistance mechanisms molecular profiling studies specific genetic profiles treatment monitoring strategies |
| gptkbp:is_noted_for |
gptkb:literature
|
| gptkbp:is_recognized_as |
gptkb:2002
|
| gptkbp:is_recognized_by |
genetic testing
|
| gptkbp:is_studied_for |
personalized medicine approaches
|
| gptkbp:is_studied_in |
clinical research
|
| gptkbp:prevalence |
found in approximately 40-60% of melanoma cases
|
| gptkbp:promoter |
gptkb:BRAF
|
| gptkbp:risk_factor |
poor prognosis
|
| gptkbp:screenings |
patients with advanced melanoma
|
| gptkbp:targets |
BRAF inhibitors
|
| gptkbp:treatment |
targeted therapy
|
| gptkbp:bfsParent |
gptkb:dabrafenib
|
| gptkbp:bfsLayer |
6
|